Eletriptan

Overview

Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

Indication

For the acute treatment of migraine with or without aura in adults.

Associated Conditions

Migraine With Aura
Migraine Without Aura

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury	2024/11/06	NCT06677229	Phase 1	Not yet recruiting	Technophage, SA
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan	2013/11/21	NCT01989936	Phase 3	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study	2013/11/18	NCT01986088	Phase 3	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo	2013/11/18	NCT01986270	Phase 3	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine	2013/11/07	NCT01978496	Phase 3	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study	2013/05/22	NCT01859481	Phase 3	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine	2011/01/14	NCT01276977	Not Applicable	Completed	California Medical Clinic for Headache
Eletriptan Pharmacokinetics In Korean Males	2010/06/08	NCT01139515	Phase 1	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
BI 44370 TA in Acute Migraine Attack	2008/09/12	NCT00751803	Phase 2	Completed	Boehringer Ingelheim
Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfully Treated With Nonsteroidal Anti-inflammatory Drugs	2008/03/13	NCT00634985	Phase 4	Completed	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
eletriptan hydrobromide	Ajanta Pharma USA Inc.	27241-040	ORAL	40 mg in 1 1	11/22/2021
Eletriptan HBR	Direct_Rx	72189-439	ORAL	40 mg in 1 1	3/27/2023
eletriptan hydrobromide	Ajanta Pharma USA Inc.	27241-039	ORAL	20 mg in 1 1	11/22/2021
Eletriptan Hydrobromide	Mylan Pharmaceuticals Inc.	0378-4287	ORAL	20 mg in 1 1	12/19/2018
Relpax	ROERIG	0049-2330	ORAL	20 mg in 1 1	3/11/2020
Eletriptan Hydrobromide	Mylan Pharmaceuticals Inc.	0378-4288	ORAL	40 mg in 1 1	12/19/2018
Eletriptan hydrobromide	Zydus Pharmaceuticals USA Inc.	68382-922	ORAL	20 mg in 1 1	9/18/2023
Eletriptan Hydrobromide	Teva Pharmaceuticals USA, Inc.	0093-8311	ORAL	40 mg in 1 1	7/25/2023
Eletriptan Hydrobromide	Amneal Pharmaceuticals LLC	65162-042	ORAL	20 mg in 1 1	8/19/2021
Eletriptan Hydrobromide	Amneal Pharmaceuticals LLC	65162-043	ORAL	40 mg in 1 1	8/19/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
RELPAX TABLET 40 mg	Pfizer Italia S.r.l.	SIN11767P	TABLET, FILM COATED	40 mg	1/14/2002

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
ELTRIPAX eletriptan (as hydrobromide monohydrate) 80mg film coated tablet blister pack	297663	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
ELYSS eletriptan (as hydrobromide monohydrate) 80mg film coated tablet blister pack	297665	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
ELETRIPTAN GPPL eletriptan (as hydrobromide monohydrate) 80mg film coated tablet blister pack	297667	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
ELPAXTAN eletriptan (as hydrobromide monohydrate) 80mg film coated tablet blister pack	297672	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
ELETRIPTAN GPPL eletriptan (as hydrobromide monohydrate) 40mg film coated tablet blister pack	297662	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
ELETX eletriptan (as hydrobromide monohydrate) 40mg film coated tablet blister pack	297671	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
RELPAX eletriptan hydrobromide 40 mg tablet blister pack	68356	Viatris Pty Ltd	Medicine	A	10/13/2000
ELETRIPTAN GENPAR eletriptan (as hydrobromide monohydrate) 80mg film coated tablet blister pack	297666	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	5/21/2019
RELPAX MIGRAINE eletriptan hydrobromide 40 mg tablet blister pack	347050	Viatris Pty Ltd	Medicine	A	12/16/2020
RELPAX eletriptan hydrobromide 80 mg tablet blister pack	68358	Viatris Pty Ltd	Medicine	A	10/13/2000

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Triptans Outperform Newer Migraine Drugs in Efficacy, Meta-Analysis Shows

10 months ago

• A comprehensive meta-analysis reveals that older triptan medications, like eletriptan, are more effective for acute migraine treatment than newer gepants. • The study suggests eletriptan, rizatriptan, sumatriptan, and zolmitriptan offer superior pain relief and sustained pain freedom compared to lasmiditan, rimegepant and ubrogepant. • Researchers recommend triptans as a first-line treatment for migraines, given their efficacy and lower cost, but note contraindications for patients with cardiovascular issues. • The analysis highlights the underutilization of triptans in migraine management, urging healthcare professionals to consider them as a preferred option.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access